Acelyrin Inc SLRN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
-
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery
-
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
-
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
-
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
-
Stocks to Watch: Oracle, Acelyrin, Humacyte
Trading Information
- Previous Close Price
- $4.88
- Day Range
- $4.89–5.03
- 52-Week Range
- $3.36–10.71
- Bid/Ask
- $4.65 / $5.50
- Market Cap
- $492.05 Mil
- Volume/Avg
- 164,731 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.11%
Company Profile
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 130
- Website
- https://www.acelyrin.com
Comparables
Valuation
|
Metric
|
SLRN
|
HRTX
|
CRMD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.86 | — | 9.63 |
Price/Sales | — | 2.25 | 572.38 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SLRN
|
HRTX
|
CRMD
|
|---|---|---|---|
Quick Ratio | 7.77 | 1.76 | 4.12 |
Current Ratio | 7.86 | 2.38 | 4.79 |
Interest Coverage | — | — | −1,599.40 |
Quick Ratio
SLRN
HRTX
CRMD
Profitability
|
Metric
|
SLRN
|
HRTX
|
CRMD
|
|---|---|---|---|
Return on Assets (Normalized) | −31.90% | −11.68% | −66.44% |
Return on Equity (Normalized) | −34.95% | — | −77.20% |
Return on Invested Capital (Normalized) | −40.49% | −18.15% | −81.35% |
Return on Assets
SLRN
HRTX
CRMD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Jsqchwrb | Xshzm | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Qwwcxxrk | Vdsgwxh | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nbjpmhg | Bvhhgv | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Chhdhqxk | Rwscbn | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Kkqcrps | Lxbl | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Rcnpstzz | Mxh | $28.1 Bil | |||
| Moderna Inc
MRNA
| Smjtmqmj | Kfqqs | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Nsgqptdk | Xzzx | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Tmrngdqv | Smwmjsz | $13.4 Bil | |||
| Incyte Corp
INCY
| Vlgltryd | Qnkvsvn | $12.7 Bil |
United States